Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
29 Jan 2019

Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.

Cognitive behavioural strategies yield modest reductions in symptoms in advanced cancer

14 Sep 2018
Singling out the DNA of HPV as a routine test proven to significantly locate pre-cancerous lesions

Cognitive behavioural strategies (CBS) may provide only small therapeutic relief for advanced cancer patients receiving treatment and experiencing co-occurring pain, sleep disturbance and fatigue, a recent study has found.

Researchers enrolled 164 advanced cancer patients who were undergoing chemotherapy. Participants randomly received a CBS intervention (n=85; mean age 58.44±9.89 years; 72 percent female), involving nature imagery and relaxation exercises, or cancer education (n=79; mean age 58.61±9.03 years; 75 percent female), which included recordings of educational materials.

Groups demonstrated statistically comparable symptom cluster severity scores at follow-up weeks 3, 6 and 9. The same was true for symptom cluster scores for interference with daily life. In terms of symptom cluster distress, the CBS group showed significantly lower mean scores at week 6 (1.82 vs 2.15; p=0.04), but scores were similar at weeks 3 and 9.

In comparison, user perception was better for the CBS intervention, which more participants enjoyed than the cancer education control (67 percent vs 36 percent). Similarly, more participants in the CBS group reported perceived improvement in symptoms (65 percent vs 18 percent) and felt greater control over their symptoms (46 percent vs 24 percent).

“The CBS intervention may provide some small therapeutic benefit for patients experiencing co-occurring pain, fatigue and sleep disturbance. Clinicians can encourage self-management of this symptom cluster by identifying strategies that reduce stress, enhance positive expectations and foster perceptions of personal control over symptoms,” said researchers.

Future studies should focus on the development of effective interventions and strategies that may help relieve the burden of co-occurring symptoms, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 
29 Jan 2019
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
29 Jan 2019
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
29 Jan 2019

Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.